Sutro Biopharma price to sales ratio STRO

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 3.4×
8-year median: 5.0×
Against its 8-year history: 28th; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.7× to 26.8×
Peer median: 2.2×

Sutro Biopharma's price to sales ratio is 3.4× as of Oct 23, 2026.

That is below its 8-year median of 5.0×, lower than on 72% of days in the last 8 years.

Over that time it ranged from 0.7× in Aug 2025 to 26.8× in Mar 2021.

The median for 10 healthcare stocks of a similar size is 2.2×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.4×	0.9×	7.6×
2025	0.9×	0.7×	1.5×
2024	1.0×	1.0×	6.2×
2023	5.4×	2.2×	6.8×
2022	6.7×	3.4×	8.3×
2021	11.6×	11.1×	26.8×
2020	18.3×	4.1×	19.3×
2019	5.0×	4.0×	7.0×

Against its peers

Companies in Healthcare nearest Sutro Biopharma's size, closest first, today.

Company	Price to sales ratio
STROSutro Biopharma	3.4×
PDEXPro DEX	2.6×
PLXProtalix BioTherapeutics	2.5×
NATRNatures Sunshine Products	0.4×
ELMDElectromed	3.0×
UTMDUtah Medical Products	6.5×
KEQUKewaunee Scientific	0.3×
ICCCImmucell	3.0×
INFUInfuSystem	1.9×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
Peer median	2.2×

Where Sutro Biopharma ranks

#15of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Sutro Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.